Sarcoma botryoides cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Sarcoma botryoides Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Sarcoma botryoides from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratpory Tests
Pelvic X Ray
MRI
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sarcoma botryoides cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sarcoma botryoides cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sarcoma botryoides cost-effectiveness of therapy
CDC on Sarcoma botryoides cost-effectiveness of therapy
Sarcoma botryoides cost-effectiveness of therapy in the news
Blogs on Sarcoma botryoides cost-effectiveness of therapy
Directions to Hospitals Treating Sarcoma botryoides
Risk calculators and risk factors for Sarcoma botryoides cost-effectiveness of therapy

Overview

Sarcoma botryoides, also known as embryonal rhabdomyosarcoma, is a type of rhabdomyosarcoma in the vagina of young girls, typically younger than 8. The name comes from the gross appearance of "grape bunches" (botryoid in Greek).